NCT05517239View on ClinicalTrials.gov

Gemcitabine With Oxaliplatin (GEMOX) in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 1, 2015

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2020

Conditions
Hepatocellular Carcinoma, Unresectable, Advanced
Interventions
DRUG

Gemcitabine, Oxaliplatin

Gemcitabine 1,000 mg/m2 infusion for 30minutes and followed by oxaliplatin 100mg/m2 infusion for 2hours on day1. All drugs were administered intravenously until progression, intolerance, patient withdrawal, or death.

Trial Locations (1)

Unknown

Yonsei University Health System, Severance Hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT05517239 - Gemcitabine With Oxaliplatin (GEMOX) in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment | Biotech Hunter | Biotech Hunter